請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77814
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺 | zh_TW |
dc.contributor.advisor | Ji-Wang Chern | en |
dc.contributor.author | 吳昆達 | zh_TW |
dc.contributor.author | Kuen-Da Wu | en |
dc.date.accessioned | 2021-07-11T14:35:20Z | - |
dc.date.available | 2024-02-28 | - |
dc.date.copyright | 2018-10-11 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 1. Marusyk, A.; Polyak, K. Tumor heterogeneity: causes and consequences. Biochim Biophys. Acta. 2010, 1805, 105–117.
2. Yakisich, J. S. Challenges and limitations of targeting cancer stem cells and/or the tumour microenvironment. Drugs and Therapy Studies 2012, 2, 48–55. 3. Groenendijk, F. H.; Bernards, R. Drug resistance to targeted therapies: deja vu all over again. Mol. Oncol. 2014, 8, 1067–83. 4. Doherty, M.; Metcalfe, T.; Guardino, E.; Peters, E.; Ramage, L. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 2016, 27, 1644–1646. 5. Bozic, I.; Reiter, J. G.; Allen, B.; Antal, T.; Chatterjee, K.; Shah, P.; Moon, Y. S.; Yaqubie, A.; Kelly, N.; Le, D. T.; Lipson, E. J.; Chapman, P. B.; Diaz, L. A., Jr.; Vogelstein, B.; Nowak, M. A. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013, 2, e00747. 6. Li, F.; Zhao, C.; Wang, L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int. J. Cancer 2014, 134, 1257–1269. 7. Lopez, J. S.; Banerji, U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat. Rev. Clin. Oncol. 2017, 14, 57–66. 8. Dahl, G.; Akerud, T. Pharmacokinetics and the drug-target residence time concept. Drug Discov. Today 2013, 18, 697–707. 9. Copeland, R. A. The drug-target residence time model: a 10-year retrospective. Nat. Rev. Drug Discov. 2016, 15, 87–95. 10. Oprea, T. I. Current trends in lead discovery: Are we looking for the appropriate properties? Mol. Divers. 2000, 5, 199–208. 11. Jin, M.; Petronella, B. A.; Cooke, A.; Kadalbajoo, M.; Siu, K. W.; Kleinberg, A.; May, E. W.; Gokhale, P. C.; Schulz, R.; Kahler, J.; Bittner, M. A.; Foreman, K.; Pachter, J. A.; Wild, R.; Epstein, D.; Mulvihill, M. J. Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics. ACS Med. Chem. Lett. 2013, 4, 627–631. 12. Bauer, R. A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov. Today 2015, 20, 1061–1073. 13. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 2011, 54, 1961–2004. 14. Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y. L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.; Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; McTigue, M.; Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 2014, 57, 4720–4744. 15. William, A. D.; Lee, A. C.; Blanchard, S.; Poulsen, A.; Teo, E. L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E. T.; Goh, K. C.; Ong, W. C.; Goh, S. K.; Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J. M.; Dymock, B. W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J. Med. Chem. 2011, 54, 4638–4658. 1. Yakisich, J. S. Challenges and limitations of targeting cancer stem cells and/or the tumour microenvironment. Drugs and Therapy Stud. 2012, 2, 48–55. 2. Niederst, M. J.; Engelman, J. A. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer. Sci. Signal. 2013, 6, 1–6. 3. Jimeno, A.; Hidalgo, M. Multitargeted therapy: can promiscuity be praised in an era of political correctness? Crit. Rev. Oncol. Hematol. 2006, 59, 150–158. 4. Reid, A.; Vidal, L.; Shaw, H.; de Bono, J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer 2007, 43, 481–489. 5. Janku, F.; Hong, D. S.; Fu, S.; Piha-Paul, S. A.; Naing, A.; Falchook, G. S.; Tsimberidou, A. M.; Stepanek, V. M.; Moulder, S. L.; Lee, J. J.; Luthra, R.; Zinner, R. G.; Broaddus, R. R.; Wheler, J. J.; Kurzrock, R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014, 6, 377–387. 6. Musgrove, E. A.; Caldon, C. E.; Barraclough, J.; Stone, A.; Sutherland, R. L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11, 558–572. 7. Kisqali and Femara Co-Pack. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. 8. Chen, Z.; Han, L.; Xu, M.; Xu, Y.; Qian, X. Rationally Designed Multitarget Anticancer Agents. Curr. Med. Chem. 2013, 20, 1694–1714. 9. Morphy, R.; Rankovic, Z. Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges. Curr. Pharm. Des. 2009, 15, 587–600. 10. Lee, K. M.; Lee, K. W.; Byun, S.; Jung, S. K.; Seo, S. K.; Heo, Y. S.; Bode, A. M.; Lee, H. J.; Dong, Z. 5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer. Cancer. Prev. Res. 2010, 3, 454–465. 11. Lee, K. W.; Bode, A. M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer 2011, 11, 211–218. 12. Korcsmaros, T.; Szalay, M. S.; Bode, C.; Kovacs, I. A.; Csermely, P. How to design multi-target drugs. Expert. Opin. Drug Discov. 2007, 2, 799–808. 13. Chaudhuri, A.; Chant, J. Protein-interaction mapping in search of effective drug targets. Bioessays 2005, 27, 958–969. 14. Geromichalos, G. D.; Alifieris, C. E.; Geromichalou, E. G.; Trafalis, D. T. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I. J. Buon. 2016, 21, 764–779. 15. Zhang, J.; Yu, X. H.; Yan, Y. G.; Wang, C.; Wang, W. J. PI3K/Akt signaling in osteosarcoma. Clin. Chim. Acta. 2015, 444, 182–192. 16. Lee, D. E.; Lee, K. W.; Song, N. R.; Seo, S. K.; Heo, Y. S.; Kang, N. J.; Bode, A. M.; Lee, H. J.; Dong, Z. 7,3',4'-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase. J. Biol. Chem. 2010, 285, 21458–21466. 17. Dienstmann, R.; De Dosso, S.; Felip, E.; Tabernero, J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol. Oncol. 2012, 6, 15–26. 18. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237–46. 19. Song, X. Targeting of both PI3K/Akt/mTOR pathway and mutant EGFR to overcome resistance to tyrosine kinase inhibitors in mutant EGFR-mediated lung cancer. Onco. Reviews 2013, 1, 13–19. 20. HERRERA, V. A.; ZEINDL-EBERHART, E.; JUNG, A.; HUBER, R. M.; BERGNER, A. The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines. Anticancer Res. 2011, 31, 849–854. 21. Tan, C.-S.; Gilligan, D.; Pacey, S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015, 16, e447–e459. 22. Sullivan, I.; Planchard, D. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front. Med. 2016, 3, 1–13. 23. Dancey, J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7, 209–219. 24. Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10, 868–880. 25. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278–2287. 26. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7, 1851–1863. 27. Liu, Q.; Chang, J. W.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D. M.; Gray, N. S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 7146–7155. 28. Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.; Gray, N. S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2( 1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473–1480. 29. Ma, X.; Lv, X.; Qiu, N.; Yang, B.; He, Q.; Hu, Y. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation. Bioorg. Med. Chem. 2015, 23, 7585–7596. 30. Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A. 6-Substituted-4-(3-bromophenylamino quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J. Med. Chem. 2001, 44, 2719–2734. 31. Hamed, M. M.; Abou El Ella, D. A.; Keeton, A. B.; Piazza, G. A.; Engel, M.; Hartmann, R. W.; Abadi, A. H. Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. MedChemComm 2013, 4, 1202–1207. 32. Chandregowda, V.; Rao, G. V.; Reddy, G. C. Convergent Approach for Commercial Synthesis of Gefitinib and Erlotinib. Org. Process Res. Dev. 2007, 11, 813–816. 33. Rosenthal, A. S.; Tanega, C.; Shen, M.; Mott, B. T.; Bougie, J. M.; Nguyen, D. T.; Misteli, T.; Auld, D. S.; Maloney, D. J.; Thomas, C. J. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg. Med. Chem. Lett. 2011, 21, 3152–3158. 1. Segaliny, A. I.; Tellez-Gabriel, M.; Heymann, M. F.; Heymann, D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J. Bone Oncol. 2015, 4, 1–12. 2. Linggi, B.; Carpenter, G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006, 16, 649–656. 3. Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001, 8, 161–173. 4. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134. 5. Oda, K.; Matsuoka, Y.; Funahashi, A.; Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1, 2005–2010. 6. Nyati, M. K.; Morgan, M. A.; Feng, F. Y.; Lawrence, T. S. Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 2006, 6, 876–885. 7. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139. 8. Kuan, C.-T.; Wikstrand, C. J.; Bigner, D. D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 2001, 8, 83–96. 9. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 2237–2246. 10. Jia, Y.; Yun, C. H.; Park, E.; Ercan, D.; Manuia, M.; Juarez, J.; Xu, C.; Rhee, K.; Chen, T.; Zhang, H.; Palakurthi, S.; Jang, J.; Lelais, G.; DiDonato, M.; Bursulaya, B.; Michellys, P. Y.; Epple, R.; Marsilje, T. H.; McNeill, M.; Lu, W.; Harris, J.; Bender, S.; Wong, K. K.; Janne, P. A.; Eck, M. J. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 2016, 534, 129–132. 11. Shibata, Y.; Chiba, M. The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib. Drug Metab. Dispos. 2015, 43, 375–384. 12. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulli, A. L.; Hsu, C.-Y. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett. 1997, 7, 417–420. 13. Nayak, L.; Lee, E. Q.; Wen, P. Y. Epidemiology of brain metastases. Curr. Oncol. Rep. 2012, 14, 48–54. 14. Zeng, Q.; Wang, J.; Cheng, Z.; Chen, K.; Johnstrom, P.; Varnas, K.; Li, D. Y.; Yang, Z. F.; Zhang, X. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J. Med. Chem. 2015, 58, 8200–8215. 15. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; Decrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18, 4872–4875. 16. Gorham, R. D., Jr.; Forest, D. L.; Khoury, G. A.; Smadbeck, J.; Beecher, C. N.; Healy, E. D.; Tamamis, P.; Archontis, G.; Larive, C. K.; Floudas, C. A.; Radeke, M. J.; Johnson, L. V.; Morikis, D. New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J. Med. Chem. 2015, 58, 814–826. 17. Leu, Y.-L.; Chen, C.-S.; Wu, Y.-J.; Chern, J.-W. Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy. J. Med. Chem. 2008, 51, 1740–1746. 18. Morphy, R. The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds. J. Med. Chem. 2006, 49, 2969–2978. 19. Oprea, T. I. Current trends in lead discovery: Are we looking for the appropriate properties? Mol. Divers. 2000, 5, 199–208. 20. Tehler, U.; Fagerberg, J. H.; Svensson, R.; Larhed, M.; Artursson, P.; Bergstrom, C. A. Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice. J. Med. Chem. 2013, 56, 2690–2694. 21. Tareke, E.; Rydberg, P.; Karlsson, P.; Eriksson, S.; Tornqvist, M. Analysis of Acrylamide, a Carcinogen Formed in Heated Foodstuffs. J. Agric. Food Chem. 2002, 50, 4998–5006. 22. Virk-Baker, M. K.; Nagy, T. R.; Barnes, S.; Groopman, J. Dietary acrylamide and human cancer: a systematic review of literature. Nutr. Cancer 2014, 66, 774–790. 23. H. K. Gibson, US Pat. Appl. 1998, US5770599. 24. R. C. Schnur, US Pat. Appl. 1998, US5747498. 25. Marzaro, G.; Guiotto, A.; Pastorini, G.; Chilin, A. A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines. Tetrahedron 2010, 66, 962–968. 26. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase. Cancer Res. 1997, 57, 4838–4848. 27. Jablonski, M. Energetic and geometrical evidence of nonbonding character of some intramolecular halogen...oxygen and other Y...Y interactions. J. Phys. Chem. A 2012, 116, 3753–3764. 28. Jaramillo, M. L.; Banville, M.; Collins, C.; Paul-Roc, B.; Bourget, L.; O'Connor-McCourt, M. Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol. Ther. 2014, 7, 557–568. 29. Cavallo, G.; Metrangolo, P.; Milani, R.; Pilati, T.; Priimagi, A.; Resnati, G.; Terraneo, G. The Halogen Bond. Chem. Rev. 2016, 116, 2478–2601. 30. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual computational chemistry laboratory - design and description, J. Comput. Aid. Mol. Des. 2005, 19, 453–463. 31. Wenlock, M. C.; Potter, T.; Barton, P.; Austin, R. P. A method for measuring the lipophilicity of compounds in mixtures of 10. J. Biomol. Screen. 2011, 16, 348–355. 32. Arnold, L. A.; Estebanez-Perpina, E.; Togashi, M.; Jouravel, N.; Shelat, A.; McReynolds, A. C.; Mar, E.; Nguyen, P.; Baxter, J. D.; Fletterick, R. J.; Webb, P.; Guy, R. K. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 2005, 280, 43048–43055. 33. Flanagan, M. E.; Abramite, J. A.; Anderson, D. P.; Aulabaugh, A.; Dahal, U. P.; Gilbert, A. M.; Li, C.; Montgomery, J.; Oppenheimer, S. R.; Ryder, T.; Schuff, B. P.; Uccello, D. P.; Walker, G. S.; Wu, Y.; Brown, M. F.; Chen, J. M.; Hayward, M. M.; Noe, M. C.; Obach, R. S.; Philippe, L.; Shanmugasundaram, V.; Shapiro, M. J.; Starr, J.; Stroh, J.; Che, Y. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J. Med. Chem. 2014, 57, 10072–10079. 1. Lempiainen, H.; Halazonetis, T. D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28, 3067–3073. 2. Lipton, J. O.; Sahin, M. The neurology of mTOR. Neuron 2014, 84, 275–291. 3. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18, 1926–1945. 4. Abraham, R. T.; Wiederrecht, G. J. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 1996, 14, 483–510. 5. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278–2287. 6. Harrison, D. E.; Strong, R.; Sharp, Z. D.; Nelson, J. F.; Astle, C. M.; Flurkey, K.; Nadon, N. L.; Wilkinson, J. E.; Frenkel, K.; Carter, C. S.; Pahor, M.; Javors, M. A.; Fernandez, E.; Miller, R. A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460, 392–395. 7. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5, 671–688. 8. Tsang, C. K.; Qi, H.; Liu, L. F.; Zheng, X. F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 12, 112–124. 9. Palavra, F.; Robalo, C.; Reis, F. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxid. Med. Cell Longev. 2017, 2017, 9820181. 10. Xie, J.; Wang, X.; Proud, C. G. mTOR inhibitors in cancer therapy. F1000Res 2016, 5, 2078. 11. Zhang, Y. J.; Duan, Y.; Zheng, X. F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 2011, 16, 325–331. 12. Tanneeru, K.; Guruprasad, L. Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J. Mol. Model 2012, 18, 1611–1624. 13. Liu, Q.; Chang, J. W.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D. M.; Gray, N. S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 7146–7155. 14. Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.; Gray, N. S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473–1480. 15. Ma, X.; Lv, X.; Qiu, N.; Yang, B.; He, Q.; Hu, Y. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation. Bioorg. Med. Chem. 2015, 23, 7585–7596. 16. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002, 45, 2615–2623. 17. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235–249. 18. Mallinson, J.; Collins, I. Macrocycles in new drug discovery. Future Med. Chem. 2012, 4, 1409–1438. 19. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery--an underexploited structural class. Nat. Rev. Drug Discov. 2008, 7, 608–624. 20. Tsvetkov, A. V.; Latyshev, G. V.; Lukashev, N. V.; Beletskaya, I. P. The successive substitution of halogens in 4-chloro-6-iodoquinoline by aryl groups in cross-coupling reactions with arylboronic acids. Tetrahedron Lett. 2002, 43, 7267–7270. 21. Olsson, H.; Sjo, P.; Ersoy, O.; Kristoffersson, A.; Larsson, J.; Norden, B. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Bioorg. Med. Chem. Lett. 2010, 20, 4738–4740. 22. Yu, X.; Sun, D. Macrocyclic drugs and synthetic methodologies toward macrocycles. Molecules 2013, 18, 6230–6268. 1. Zeng, Q.; Wang, J.; Cheng, Z.; Chen, K.; Johnstrom, P.; Varnas, K.; Li, D. Y.; Yang, Z. F.; Zhang, X. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J. Med. Chem. 2015, 58, 8200–8215. 2. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5, 671–688. 3. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 2009, 8, 2204–2210. 4. Liu, Q.; Chang, J. W.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D. M.; Gray, N. S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 7146–7155. 5. Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.; Gray, N. S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl)benzo[h][1,6]naphthyridin-2( 1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473–1480. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77814 | - |
dc.description.abstract | 本論文之研究主題為設計與合成一系列以喹唑啉和喹啉作為骨架的新穎衍生物,並探討其作為激酶抑制劑的生物活性。喹唑啉和喹啉的主結構廣泛應用於藥物設計上,尤其在表皮生長因子受體抑制劑與哺乳動物雷帕黴素靶蛋白抑制劑中尤為常見。利用文獻中已發表這兩類抑制劑的分子為設計基礎,找出其中結構高度相似的Torin 2 與Lapatinib,並以合併設計的方式開發出一系列表皮生長因子受體與哺乳動物雷帕黴素靶蛋白的雙重抑制劑。
在開發雙重抑制劑研究中,發現到4-取代-6-(1-甲基吡唑-4-取代)-喹唑啉和4-取代-6-(嘧啶-5-取代)-喹唑啉是具有開發潛力的骨架,並以此結果進一步發現分子25j同時具有對表皮生長因子受體和哺乳動物雷帕黴素靶蛋白的抑制效果。此項研究提供了具有表皮生長因子受體和哺乳動物雷帕黴素靶蛋白雙重抑制劑特性的新穎分子架構,並具有潛力可作為臨床治療藥劑。 在開發表皮生長因子受體抑制劑的研究中,我們發現到丙烯醯胺基能有效提高化合物Gefitinib和AZD3759在1-辛醇和pH7.4水溶液中的溶解度。也由於這項物理性質的提升,其結果也直接反應在抑制癌細胞增殖,特別是在表皮生長因子受體過度表現的A549細胞株中尤為顯著。其中以化合物2a對表皮生長因子受體和A549細胞株抑制最為突出。 在開發哺乳動物雷帕黴素靶蛋白抑制劑的研究中,利用新開發的合成途徑交聯四號與六號位喹啉形成大環分子,並進一步發現到化合物39以聚醚為鏈結,連結喹啉的四號與六號位所形成的二十一員環具有相當的抑制效果。此項研究提供了以喹啉為基礎結構的大環分子合成方法,並可作為哺乳動物雷帕黴素靶蛋白抑制劑開發的方向。 因此,本論文製備了兩種具有潛力可作為癌症治療的先導化合物。其中一個化合物25j具有表皮生長因子受體和哺乳動物雷帕黴素靶蛋白的雙重抑制性,另一個是具有二十一員環的化合物39能夠抑制哺乳動物雷帕黴素靶蛋白。此外,丙烯醯胺基在藥物的開發上,有助於改善分子的物化性質進而提升溶解度與細胞膜的穿透度。 | zh_TW |
dc.description.abstract | The aim of this dissertation is to design, synthesize, and biologically evaluate novel kinase inhibitors with quinazoline and quinoline skeleton. Quinazoline and quinoline are considered to be ideal scaffolds for drug design. To develop a dual inhibitor, the key substructures of mTOR and EGFR inhibitors were merged using Torin 2 and Lapatinib as a lead, respectively.
Two series of novel scaffold 4-substituted-6-(1-methylpyrazol-4-yl)quinazoline and 4-substituted-6-(pyrimidin-5-yl)quinazoline were synthesized and demonstrated the potential inhibition on these two enzyme. Compound 25j was identified as a dual inhibitor of the kinases mTOR and EGFR with IC50 values of 2.02 μM and 0.54 μM, respectively. This investigation provided a new scaffold for the development of potent mTOR and EGFR dual inhibitor as potential clinically therapeutic agent. For the development of EGFR inhibitors, an acrylamide group was added onto the EGFR inhibitors such as gefitinib and AZD3759 and the data were found to improve the solubility in 1-octanol and pH7.4 aqueous solutions. However, these physicochemical properties were directly corresponding to their cancer cell anti-proliferation assay. This series of compounds led to identification of compound 2a as potent inhibitor against EGFR with an IC50 value of 65.2 nM and against the A549 cell line with an IC50 value of 0.15 μM. For the development of mTOR inhibitors using macrocycles concept, a novel approach toward the synthesis of macrocycle ring based on quinoline as scaffold was established. We found out that compound 39 with 21-membered ring of polyether cross-linking 4- and 6-position of quinoline showed good activity against mTOR with an IC50 value of 8.89 μM. This study provided a new direction for the preparation of macrocycles base on quinoline as potential mTOR inhibitors. In summary, this dissertation has provided two new leads for the further development of potential anti-cancer agents. One is compound 25j as a dual inhibitor of the kinases mTOR and EGFR, and the other one is compound 39 with 21-membered ring macrocycle against mTOR. Besides, the physicochemical properties of acrylamide can be applied to be included in the molecule to improve solubility and cell permeability in the drug development. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:35:20Z (GMT). No. of bitstreams: 1 ntu-107-D01423102-1.pdf: 4174645 bytes, checksum: 5b18410a3e3839984ce03aad15c8a26a (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 摘要……………………………………………………………………......…. i
Abstrate………………………………………………………………….…… iii Content……………………………………………………………….………. v List of Figure………………………………………………………………..... vii List of Scheme…………………………………………………………….…. ix List of Table…………………………………………………………….……. x List of Abbreviation…………………………………………………….……. xi Chapter 1 Introduction 1.1 Targeted Therapies for Precision Medicine in Oncology…... 1 1.2 Macrocycles in Drug Discovery………………..…………... 4 1.3 References…………………………………………………... 8 Chapter 2 Structure-Based Design and Synthesis of Quinazoline Derivatives as mTOR/EGFR Dual Inhibitors 2.1 Introduction…………………………………………………. 11 2.2 Rational Design……………………………………………... 16 2.3 Retrosynthetic Analysis……………………………………... 19 2.4 Results and Discussion 2.4.1 Chemistry…………………………………………... 20 2.4.2 Biological Evaluation……………………...………. 31 2.5 Summary……………………………………………………. 38 2.6 Experimental Section….……………………………………. 39 2.7 References…………………………………………………... 81 Chapter 3 Optimization of EGFR Inhibitors with Improved Physicochemical Properties 3.1 Introduction…………………………………………………. 86 3.2 Design and Synthesis……………………………………….. 91 3.3 Results and Discussion……………………………………… 93 3.4 Summary……………………………………………………. 99 3.5 Experimental Section….……………………………………. 100 3.6 References…………………………………………………... 118 Chapter 4 Structure-Based Design and Synthesis of Quinoline Derivatives as Potential mTOR Inhibitors 4.1 Introduction…………………………………………………. 123 4.2 Rational Design……………………………………………... 129 4.3 Retrosynthetic Analysis……………………………………... 130 4.4 Results and Discussion 4.4.1 Chemistry………………………………………….. 131 4.4.2 Biological Evaluation……………………...………. 141 4.5 Summary……………………………………………………. 143 4.6 Experimental Section………………………………………. 144 4.7 References…………………………………………………... 152 Chapter 5 Conclusions and Perspectives 5.1 EGFR Inhibitor…………………………………………...… 155 5.2 mTOR Inhibitor……………………………………………... 157 5.3 References…………………………………………………... 160 | - |
dc.language.iso | en | - |
dc.title | 設計與合成喹唑啉和喹啉衍生物作為蛋白激酶抑制劑及生物活性評估 | zh_TW |
dc.title | Design, Synthesis, and Biological Evaluation of Quinazoline and Quinoline Derivatives as Kinase Inhibitors | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-2 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 顧記華;忻凌偉;梁碧惠;陳香惠 | zh_TW |
dc.contributor.oralexamcommittee | Jih-Hwa Guh;Ling-Wei Hsin;Pi-Hui Liang;Grace Shiahuy Chen | en |
dc.subject.keyword | ?唑?,??,表皮生長因子受體抑制劑,哺乳動物雷帕黴素靶蛋白抑制劑,丙烯醯胺,大環, | zh_TW |
dc.subject.keyword | quinazoline,quinoline,EGFR inhibitor,mTOR inhibitor,acrylamide,macrocycles, | en |
dc.relation.page | 160 | - |
dc.identifier.doi | 10.6342/NTU201800891 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-06-20 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 藥學研究所 | - |
dc.date.embargo-lift | 2028-01-01 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-2.pdf 目前未授權公開取用 | 4.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。